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Introduction
Cardiac fibroblasts are cells of mesenchymal nature that reside within the cardiac
interstitium[1, 2]. They comprise the majority of the cells in the adult rodent and human
heart and express proteins that maintain homeostasis of the extracellular matrix (ECM)[3,
4]. The interconnected network of cardiac fibroblasts forms the fibrous skeleton of the heart
and serves as a scaffold for supporting all cardiac cell types. Aside from maintenance of the
extracellular matrix, cardiac fibroblasts express a rich array of growth factors and cytokines
and communicate with adjoining myocytes to facilitate electro-mechanical transduction[1,
5]. The fibroblast also lies at the heart of most cardiac pathologies[6]. Common congenital
and adult cardiac pathologies are characterized by a loss of cardiac muscle and as the
mammalian heart is unable to robustly regenerate, lost cardiac muscle is replaced by
fibrosis. Fibrosis induces adverse changes in cardiac geometry and function that leads to
progressive chamber enlargement, hypertrophy of viable myocytes, increasing wall tension
and ultimately congestive cardiac failure[7–9]. Despite the enormous pathophysiological
importance of fibrosis in cardiac diseases, the cardiac fibroblast remains an ill-defined cell
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and very few interventions effectively target the cardiac fibroblast and fibrosis[10, 11]. This
review summarizes the role of the cardiac fibroblast in cardiac development and repair to
emphasize the emerging but central role of this cell in regulating cardiac function in health
and disease.
The Cardiac Fibroblast In Development
Developmental origin of cardiac fibroblasts
Cardiac fibroblasts are thought to be predominantly derived from the epicardium (Figure 1)
[1]. Villous like projections protrude from the venous pole of the developing heart to form
the proepicardium[12, 13]. Cells from the pro-epicardium detach and attach on the beating
ventricular surface to form the epicardium[14]. Subsequently epithelial cells of the
epicardium undergo epithelial-mesenchymal-transition (EMT) to form mesenchymal cells
that invade the developing myocardium[15]. A subset of these mesenchymal cells after EMT
acquire migratory properties and invade the developing myo-fascial planes to occupy an
interstitial position in between cardiac myocytes to become resident cardiac fibroblasts[16,
17].
Cardiac fibroblasts are observed in the developing murine heart by E12.5 days post
fertilization (dpf) and their numbers progressively increase throughout development[3].
Using flow cytometry, Banerjee et al estimated that cardiac fibroblasts comprise
approximately 14% of all murine heart cells at E18.5 dpf. Fibroblast numbers progressively
increase in the heart in post natal life comprising 27% of the total number of cells in the
adult murine heart (Table 1)[3]. In the rat heart, cardiac fibroblasts constitute approximately
30% of the total number of heart cells on the first day of life and by the 15th day of post-
natal life, they comprise approximately 2/3 of the total numbers of cells in the rat heart
(Table 2)[3, 4]. In humans, non-myocyte cells comprise approximately 70% of the total
number of cardiac cell types[18, 19]. The higher number of fibroblasts in rat and human
hearts may be related to a larger heart size, greater wall tension and consequently a need for
greater production of ECM[3].
In contrast to cardiac fibroblasts, valvular fibroblasts are thought to be derived from the
endothelium overlying the region of the cardiac cushions (site of atrio-ventricular valve
formation)[20–22]. The endothelium overlying the valve leaflets undergoes endothelial-
mesenchymal-transition (EndMT) to generate cardiac fibroblasts that invade the valvular
mesenchyme and contribute to the collagenous structure of the valve (Figure 1).
Signals regulating cardiac fibroblast formation during development
As cardiac fibroblasts are formed via EMT, signals regulating EMT affect fate specification
of epicardial cells to form fibroblasts. EMT during development is tightly regulated and
complex to analyze as different molecules exhibit species specific differences in the
regulation of EMT. Fibroblast growth factors (FGFs) are thought to promote EMT.
Members of the transforming growth factor β (TGFβ) superfamily inhibit EMT in the
developing avian heart to regulate the fraction of epicardial cells adopting a mesenchymal
phenotype[23]. Notch signaling promotes EndMT and formation of valvular fibroblasts and
disruption of Notch signaling in developing cardiac valves leads to formation of atrophic
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valves[24]. Once the epicardial cells undergo EMT, platelet derived growth factor (PDGF)
and TGFβ are thought to promote differentiation into a myofibroblast or cardiac fibroblast
phenotype. Platelet derived growth factor receptor (PDGFRα) in particular, is thought to be
required for epicardial derived cells to adopt a cardiac fibroblast fate[25]. In addition to
secreted molecules, several transcription factors such as T box transcription factor 18
(Tbx18), Wilms tumor 1 (Wt-1) and members of the snail family also regulate EMT during
development[20]. Disruption of Wt-1 in the epicardium increases Snail1 levels that
subsequently inhibits EMT and increases expression of epithelial markers[26].
Function of cardiac fibroblast during heart development
In contrast to the well described functions of the cardiac fibroblast in the adult heart, less is
known about the role of the cardiac fibroblast in heart development. The number of cardiac
fibroblasts progressively increases from E12.5 dpf and the increasing number of fibroblasts
form a fibrous skeleton that likely provides structural support for the growing number of
cardiac myocytes. Embryonic cardiac fibroblasts compared to adult cardiac fibroblasts
express more growth factors and secrete in greater abundance extracellular matrix proteins
such as periostin, fibronectin and tenascin C[27]. In co-culture experiments it was observed
that fibronectin and type 3 collagen secreted by the embryonic cardiac fibroblast induced
proliferation of embryonic cardiac myocytes via a β1 integrin receptor dependent
mechanism. These observations suggest that cardiac fibroblasts can regulate cardiomyocyte
proliferation during development (Figure 2)[27]. Cardiac fibroblasts express angiogenic
cytokines such as vascular endothelial growth factor (VEGF) and FGF. During cardiac
development, FGF and VEGF drive mesenchymal cells originating from epicardial EMT to
adopt an endothelial lineage[28]. Cardiac fibroblasts also express anti-angiogenic cytokines
such as connective tissue growth factor (CTGF)[1]. More rigorous studies are needed to
address the role of cardiac fibroblast in the regulation of angiogenesis in the embryonic
heart.
The Cardiac Fibroblast In Wound Healing
Origins of cardiac fibroblasts after cardiac injury
Fibroblasts in the injured heart are thought to have diverse origins (Figure 1). Resident
cardiac fibroblasts at the site of injury proliferate and are thought to be the predominant pool
of cardiac fibroblasts contributing to cardiac fibrosis after injury, although rigorous fate
mapping studies have not been done to confirm this[1]. Early studies using tritiated
thymidine demonstrated a small pool of proliferating perivascular cardiac fibroblasts after
cardiac injury[18, 29]. Fibrosis around the perivascular region is observed in the early stages
of many cardiac pathologic conditions and pericytes and perivascular cells represent another
population of cells contributing to fibrosis in the injured heart (Figure 1)[30, 31].
Bone marrow derived cells also contribute to cardiac fibrosis[32]. Several studies have
demonstrated that between 3 and 24% of myofibroblasts in the injured region are of bone
marrow origin[33, 34]. These circulating fibroblast precursors have been termed fibrocytes
and express hematopoietic (CD45), monocytic (CD11b) and progenitor markers (CD34).
The ability of bone marrow derived cells to contribute to cardiac fibrosis appears to be
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physiologically important as inhibition of fibrocyte recruitment diminished fibrosis and had
salutary effects on remodeling[33].
We and others have demonstrated that a subset of epicardial cells are activated after acute
cardiac injury. Epicardial derived cells undergo EMT to generate cardiac fibroblasts, thus
recapitulating a developmental program of epicardial EMT (Figure 1)[35, 36]. Following
EMT, epicardial derived cardiac fibroblasts reside in the subepicardial space, express
collagen and contribute to a pro-fibrotic repair response. Inhibition of epicardial EMT
decreased the number of epicardial derived cardiac fibroblasts but led to cardiac chamber
dilatation and worsening ejection fraction. These observations suggest that epicardial
derived cardiac fibroblasts play an important physiological role in the cardiac repair
response[35].
Endothelial cells undergo endothelial-mesenchymal transition (EndMT) and have been
reported to contribute to 30% of the cardiac fibroblasts in a murine model of pressure
overload injury[37], but the degree to which endothelial cells contribute to fibrosis in the
acutely injured heart is less certain. The physiological significance of fibroblast diversity in
the injured heart is unclear and whether different subsets of cardiac fibroblasts of diverse
origins exert disparate effects to co-ordinate a repair process remains an unanswered
question.
Function of the cardiac fibroblast in wound healing
The cardiac fibroblast plays a central role in wound healing after myocardial injury and
affects various aspects of the wound healing response from deposition of extracellular
matrix proteins to wound angiogenesis and scar maturation (Figure 2). Following acute
myocardial infarction, cardiac fibroblasts in the heart become activated and rapidly
proliferate. In rodent hearts, peak cardiac fibroblast numbers are achieved within 7–14 days
after permanent ligation of the left anterior descending coronary artery[38] and within 3
days of ischemia-reperfusion injury[39]. Four weeks after ischemia-reperfusion injury, the
number of cardiac fibroblasts decreases by 90% compared to its peak, demonstrating the
dynamic nature of the fibroblast population in the region of injury. Activated fibroblasts at
the site of injury express contractile proteins such as α-smooth muscle actin
(myofibroblasts) and secrete ECM proteins (mainly collagens). This early fibrotic repair
response is critical for maintenance of cardiac structural integrity and performance after
cardiac injury. Disruption of cardiac fibroblast activation early after injury led to impaired
wound healing and worsening cardiac performance[35].
In the later phases of wound healing (days to weeks), collagen fibers at the site of injury
undergo cross-linking which increases the tensile strength of the scar[40]. The scar
subsequently contracts undergoing a reduction in surface area and myofibroblasts expressing
contractile proteins are thought to contribute to scar contraction (Figure 2). Scar contraction
and thinning lead to adverse changes in ventricular chamber geometry and compliance. The
hemodynamic burden on the remaining viable myocytes is increased, and over time, this
leads to the development of congestive heart failure. In this section, we cover the various
roles of the cardiac fibroblast in early and late wound healing, describe the molecular
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activation of cardiac fibroblasts after cardiac injury and finally discuss how fibroblasts can
be targeted for cardiac regeneration.
Production of extracellular matrix
Homeostasis of the extracellular matrix has been traditionally considered to be the main
function of the cardiac fibroblast in the uninjured heart. The cardiac ECM consists of
interstitial collagens (predominantly type1 and type 3), proteoglycans, glycoproteins,
cytokines, growth factors and proteases[2]. Cardiac fibroblasts not only synthesize new
matrix proteins but also express various metalloproteinases (MMPs) that degrade
extracellular matrix. In the healthy heart, synthesis and breakdown of extracellular matrix
are tightly regulated, but in pathological states, increased MMP expression and activity can
lead to excessive ECM degradation and turnover[2, 41]. For instance, in patients with
dilated cardiomyopathy, characterized by progressive heart failure and fibrosis, several
MMPs including MMP2 were found to be elevated in the myocardial interstitium and
extracts of hearts exhibited higher degree of collagenase and proteolytic activity[42–44]. In
pressure overload cardiac hypertrophy in humans, MMP expression in the heart increases
with the onset of left ventricular failure. In rodent models of pressure overload cardiac
hypertrophy, increased expression of MMPs is associated with transition from compensation
to heart failure[45, 46]. These observations suggest that dynamic changes in collagen
content and turnover are associated with and perhaps contribute to cardiac pathologic states.
Following acute myocardial infarction fibroblasts not only increase the synthesis of ECM
proteins at the site of injury (replacement fibrosis) but also increase ECM protein synthesis
remote from the injury [7, 47]. The deposition of fibrous tissue in areas remote from the area
of injury has been termed reactive fibrosis[1, 48]. Reactive fibrosis contributes to the
pathophysiologic process after acute myocardial injury by altering chamber compliance and
increasing the stiffness of the ventricles. In the normal heart 85% of the collagen is type I,
while early after injury the predominant type of collagen synthesized particularly in the
injury area is type III[49]. Type III collagen is more susceptible to stretch than type I
collagen and enables the infarcted ventricle to be more distensible particularly within the
first two weeks. As the scar matures, the ratio changes with more of type I collagen
predominating than type III [49, 50].
Production of cytokines and growth factors
Cardiac fibroblasts express a rich array of cytokines and growth factors that affects wound
healing via autocrine or paracrine mechanisms[51]. The expression of cytokines is markedly
altered in diseased conditions, often contributing to the pathophysiological process. After
myocardial infarction, cardiac fibroblasts are the main source of expression of the pro-
inflammatory cytokine IL-1β[7, 52]. IL-1β enhances fibroblast migration and promotes
turnover of the cardiac ECM via inhibition of collagen type 1 and type 3 synthesis and
increased secretion of MMPs[2, 53]. Cardiac hypertrophy is usually accompanied by cardiac
fibrosis and cardiac fibroblasts express the pro-fibrotic cytokine IL-6 that promotes cardiac
fibroblast proliferation and fibrosis[54]. It is thought that mechanical stretching of the
cardiac fibroblasts, that potentially occurs secondary to cardiac dilatation or changes in
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hemodynamic burden in the heart, induces expression of pro-fibrotic cytokines, expression
of ECM proteins and ECM receptors on cardiac fibroblasts[55].
Role in wound angiogenesis
Endothelial cell proliferation accompanies fibroblast proliferation early after myocardial
injury and neovascularization of the injury region promotes wound healing and cardiac
repair, while excessive neovascularization beyond the region of injury can promote
hemorrhage[56]. Fibroblasts exist in close association to endothelial cells and are known to
express pro-angiogenic cytokines (FGF & VEGF) as well as anti-angiogenic cytokines
(PDGF & CTGF)[51][57]. Fibroblasts also express Tissue inhibitor of metalloproteinases
(TIMPs) and TIMPS are known to inhibit and promote angiogenesis in a context dependent
manner[58][59]. It is thus possible that fibroblasts contribute to the regulation of wound
angiogenesis via expression of angiogenic and anti-angiogenic molecules and more studies
will be needed to delineate the role of fibroblasts in regulating post infarct angiogenesis.
Role in electro-mechanical transduction after injury
Cardiac fibroblasts have high membrane resistance, that makes them good conductors of
electrical signals. They can physically communicate with adjoining cardiac myocytes ex-
vivo through gap junctional proteins such as connexin 43, although the physiological
relevance of such interactions in vivo has not been demonstrated[60, 61]. As fibrosis is
associated with disruption of the normal arrangement of myocytes and fibroblasts,
heterogeneity in conduction can occur around the area of fibrosis and predispose to life
threatening re-entry tachycardias. How fibroblast to fibroblast and fibroblast to myocyte
communication in the region of scar influence the genesis of arrhythmias is an active field of
investigation in arrhythmia biology.
Role in scar maturation and contraction
As alluded earlier in this review, a subset of cardiac fibroblasts after cardiac injury, acquire
new phenotypic characteristics, express α-smooth muscle actin and are known as
myofibroblasts[62]. The uninjured heart except the valvular interstitum does not have
myofibroblasts[63]. In changing their phenotype to a myofibroblast, cardiac fibroblasts are
thought to transition via an intermediate stage called proto-myofibroblast, characterized by
expression of early stress fibers such as β-actin and γ-actin[40, 64]. The proto-
myofibroblasts subsequently transition into fully differentiated myofibroblasts in the
presence of appropriate signals from the ECM as well as neighboring cells[40]. A fully
differentiated myofibroblast expresses α-smooth muscle actin but can be distinguished from
a smooth muscle cell by low expression of other smooth muscle proteins such as heavy
chain smooth muscle myosin[2].
Myofibroblasts contribute to scar contraction and remodeling[63, 65]. Scar maturation and
contraction results in decreased surface area of the scar and leads to a thinner scar with
greater tensile strength. Renewal of matrix proteins plays a critical role in persistence of
scars in other organs such as the liver [66] and myofibroblasts by continuing to turn over
matrix proteins likely perpetuate the persistence of scars in the heart[6, 18]. It is interesting
to note that in organs such as the skin that retain the ability to heal wounds without scar
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formation, myofibroblasts undergo apoptosis in the later phases of wound healing[48, 67].
Myofibroblasts have been found to be embedded in mature cardiac scars in humans years
after myocardial injury and it is not clear whether the persistence of myofibroblasts in
chronic scars months or years after cardiac injury is secondary to these cells being resistant
to apoptosis[48].
Signals regulating fibroblast activation
Modulation of signals mediating early fibroblast activation and late remodeling is an area of
intense scientific interest for its obvious therapeutic implications. An exhaustive description
of mediators and signaling pathways affecting fibroblast function after injury is beyond the
scope of this review but in this section we briefly describe some of the major signaling
pathways involved. The region of myocardial necrosis is first infiltrated with
polymorphonuclear cells. Over the first 48 hours, neutrophils are replaced by a
mononuclear/macrophage infiltrate. Macrophages in the region of injury release pro-
inflammatory cytokines, such as TNFα, IL-1β and IL-6 that play an important role in
fibroblast activation and proliferation (Figure 3)[39].
The TGFβ/SMAD axis is known to promote fibroblast activation and proliferation after
cardiac injury (Figure 3)[68]. TGFβ is markedly up-regulated in the infarcted heart with
different isoforms displaying different temporal patterns of expression[69]. TGFβ1 and
TGFβ2 are induced early while TGFβ3 shows delayed and persistent upregulation[70].
TGFβ in the acutely injured heart is expressed by macrophages as well as fibroblasts in the
injury area. Although the precise functions of the different isoforms are unclear, downstream
mediators of TGFβ (SMAD 2,3,4) are significantly elevated in the infarct area and
inhibition of the TGFβ/SMAD axis is associated with decreased fibrosis and amelioration of
late infarct remodeling[69, 71].
The renin angiotensin system (RAS) is being increasingly recognized to exert pro-fibrotic
effects[10, 72, 73]. Angiotensin II levels are elevated in the heart within days of injury and
Angiotensin II is known to enhance cardiac fibroblast proliferation and expression of
collagens[74]. The expression of angiotensin receptors is more pronounced in cardiac
fibroblasts in the injured heart[75] than on cardiac myocytes and pharmacological inhibition
of the angiotensin axis has been shown to ameliorate cardiac fibrosis[76]. Furthermore,
Angiotensin II has been shown to act upstream of TGFβ and at least in part, TGFβ mediates
effects of Angiotensin. Thus a complex interaction of the RAS and TGFB/SMAD axis may
affect post infarct remodeling (Figure 3)[75].
Endothelin-1 (ET-1) is a potent vasoconstrictor and secreted predominantly by endothelial
cells but endothelin can be expressed by inflammatory cells and fibroblasts[77].
Endothelin-1 is a downstream mediator of TGFβ and some studies suggest that ET-1 can
work with TGFβ to promote myofibroblast persistence (Figure 3)[77, 78]. Ang II can also
exert its effects via ET-1 and these studies suggest that ET-1 can work downstream of TGFβ
and Ang II to drive fibroblast activation. Endothelin antagonists are currently approved for
the treatment of pulmonary hypertension and future studies will determine their benefit in
cardiac fibrosis[79].
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Signaling systems important for cardiovascular development have also recently been shown
to regulate cardiac fibrosis and repair after acute injury. We demonstrated that epicardial
cells expressed Wnt1 after acute ischemic cardiac injury and Wnt1 expressing epicardial
cells, in a β-catenin dependent manner, underwent EMT to adopt a fibroblast phenotype[35].
A dynamic notch signaling injury response has been shown to activate the epicardium and
contribute to epicardial derived cardiac fibroblasts[36]. Thymosin β4 promotes epicardial
cell migration and differentiation of epicardial progenitors to promote
neovascularization[80]. Although currently, there is no specific therapy for the treatment of
cardiac fibrosis, the detailed dissection of signaling pathways affecting various aspects of
fibroblast activation provide fresh opportunity for targeting the cardiac fibroblast.
Fibroblasts and cardiac regeneration
More recently, reprogramming techniques have been applied to induce a fibroblast to change
fate into a cardiomyocyte (Figure 4). Cardiac fibroblasts isolated from the skin can be
transduced with a cocktail of transcription factors to create induced pluripotent stem (iPS)
cells. Such iPS cells can be differentiated in-vitro to generate patient specific
cardiomyocytes that could be transplanted into a failing or infarcted heart (Figure 4A). More
recently, direct reprogramming approaches have been described where the introduction of a
specific combination of factors can directly reprogram a cardiac fibroblast to a
cardiomyocyte without having the fibroblast transition through a primitive undifferentiated
state (Figure 4A). This technique is particularly appealing as introduction of such factors
into fibroblasts in the region of scar can potentially change the fate of a fibroblast to a
cardiac myocyte and reverse scarring (Figure 4B).
Ieda. et al demonstrated that a combination of transcription factors GATA4, Mef2C and
TBX5 (GMT) when introduced into a cardiac fibroblast are sufficient to reprogram a cardiac
fibroblast into a cardiomyoycte[81]. Moreover, the groups of Olson and Srivastava
demonstrated that such direct reprogramming can also occur in vivo. The cocktail of
transcription factors (GMT or GMT and Hand2) administered to mice hearts via retroviruses
following myocardial infarction was sufficient to reprogram scar tissue into cardiac muscle
cells that appeared to integrate with surrounding myocardium[82, 83]. Wada. et al have
more recently demonstrated that the addition of Mesp1 and Myocardin to the GMT cocktail
of transcription factors can induce human dermal fibroblasts to adopt a cardiomyogenic like
fate[84]. Jayawardena. et al showed that delivery of a combination of microRNAs is
sufficient to reprogram fibroblasts into a cardiomyogenic fate[85].
However with all the above reports, the fraction of fibroblasts undergoing successful direct
reprogramming in-vivo into cardiac muscle cells remains small. More efficient delivery
systems of transgenes or identification of novel factors that greatly increase the efficiency of
direct fibroblast-myocyte reprogramming are needed for successful manipulation of large
scars. Nevertheless, this method of directly reprogramming scar tissue into cardiomyocytes
is undeniably attractive as it has the promise of changing chronic scar tissue into cardiac
muscle cells and potentially reverse post infarct remodeling (Figure 4B).
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There is mounting clinical evidence to suggest that fibrosis is an independent predictor of
mortality and sudden death in patients with heart failure. Patients with a similar ejection
fraction but having significantly greater cardiac fibrosis have a poorer prognosis[86]. There
is no specific treatment for fibrosis and there is a dire need for major biological questions
regarding cardiac fibrosis to be answered.
In this concluding section, we discuss some of the major questions that remain unanswered
in the field of cardiac fibrosis. First, given the diversity of origin of fibroblasts contributing
to cardiac injury, are there specific subsets of fibroblasts that need to be targeted both in the
early and late phases of wound healing? Using fate mapping techniques, Kalluri’s group
recently demonstrated that after kidney injury, approximately 50% of fibroblasts in the
injury area are of interstitial origin where as the remaining pool is derived from the bone
marrow, endothelium (via endothelial-mesenchymal-transition) and epithelium (via EMT)
[87]. Recent observations made in skin wound healing also suggest that different lineages of
fibroblasts contribute to different aspects of wound healing in the skin[88]. Fibroblasts in the
lower dermis are responsible for the deposition of extracellular matrix proteins and
fibroblasts in the upper dermis are recruited only during re-epithelialization. Such concepts
of specification of fibroblasts during wound healing can be tested in the heart after
myocardial injury and can potentially identify whether specific subsets of fibroblasts should
be targeted. In this regard, rigorous fate mapping studies should also be performed in the
developing heart to identify other potential cell sources contributing to the cardiac fibroblast
pool. Elucidation of mechanisms that promote cardiac fibroblast proliferation in the
developing heart may identify new signaling pathways that regulate fibroblast activation
after cardiac injury.
Second, identification of mechanisms perpetuating the persistence of scars long after injury
are of paramount importance. In the liver, under certain circumstances, fibrosis is known to
regress and regression of hepatic scars is thought to be secondary to inadequate ECM
renewal rather than active catabolism and breakdown of collagen. Do scars in the heart
persist secondary to continuous turnover of matrix proteins by myofibroblasts? What then
are the factors driving myofibroblast turnover of ECM proteins long after cardiac injury?
Finally can cardiac fibrosis be reversed? Advances in direct reprogramming technology have
provided proof of concept that fibroblasts in cardiac scar can be directly reprogrammed into
cardiomyocytes. In theory, if a large number of myofibroblasts in the scarred region can be
coaxed to adopt a cardiac muscle fate, there should be diminution in the amount of fibrosis.
Moreover this strategy also generates new cardiac muscle in the region of scar formation
and can potentially reverse deleterious ventricular remodeling. However, pockets of newly
generated cardiomyocytes that do not integrate with surrounding cardiac muscle can lead to
the formation of arrhythmogenic foci. This technology is also currently limited by the poor
efficiency of fibroblast to cardiomyocyte reprogramming in-vivo. Optimization of transgene
delivery as well as identification of factors that enhance the efficiency of direct
reprogramming will be needed prior to translating these observations into clinical practice.
Understanding the physiologic basis of fibroblast diversity, mechanisms regulating the
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persistence of scars and manipulation of fibroblast plasticity in a spatiotemporal manner will
be key for treating pathologic cardiac fibrosis.
List of abbreviations




FGF Fibroblast growth factor
IL Interleukin
MMP Matrix metalloproteinase
TGF Transforming growth factor
PDGF Platelet derived growth factor
PDGFR Platelet derived growth factor receptor
RAS Renin-angiotensin system
TIMP Tissue inhibitor of metalloproteinase
Wt-1 Wilms tumor 1
Tbx T-box transcription factor
Mef Myocyte enhancer factor
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• Cardiac fibroblasts are the most abundant cardiac cell type
• Fibroblasts regulate cardiomyocyte proliferation during heart development
• Fibroblast activation is a critical early repair response after cardiac injury
• Persistence of fibroblasts in injury area leads to chronic scar and remodeling
• Reprogramming fibroblasts to myocytes can be a new strategy for treating
cardiac scar
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Figure 1. Origins of cardiac fibroblasts during cardiac development and following acute
ischemic injury
The cardiac fibroblast in the injured heart has diverse origins compared to the fibroblast in
the developing heart.
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Figure 2. Major functions of the fibroblast during cardiac development and wound healing
The fibroblast promotes proliferation of embryonic cardiomyocytes. It influences
angiogenesis in the adult heart, regulates ECM turnover both in the adult uninjured heart and
after acute injury. The fibroblast plays a pathophysiological role in scar contraction, adverse
remodeling and ventricular dilatation and exerts electrophysiological effects.
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Figure 3. Signaling pathways regulating pathophysiological effects of cardiac fibroblasts after
cardiac injury
Following cardiac injury, monocyte/macrophage infiltrate at the site of injury release growth
factors and cytokines that activate cardiac fibroblasts. Mechanical stretch and hypoxia in
addition are potent activators of fibroblasts. TGFβ, ET-1, Ang II and other inflammatory
cytokines such as IL-1β and IL-6 induce cardiac fibroblast proliferation, formation of
myofibroblast, deposition of extracellular matrix and matrix turnover. The fibroblast itself
expresses many of these pro-fibrotic cytokines that exert effects via autocrine/paracrine
mechanisms. Cytokines expressed by cardiac fibroblasts also induce cardiomyocyte
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hypertrophy. Persistence of myofibroblasts in the injury region leads to continuing matrix
turnover, formation of chronic scar and along with myocyte hypertrophy leads to adverse
ventricular remodeling. (TGFβ: Transforming Growth Factor β, IL: Interleukin, ET-1:
Endothelin 1, Ang II: Angiotensin II, bFGF: Basic Fibroblast Growth Factor, PDGF: Platelet
Derived Growth Factor, TNFα: Tumor Necrosis Factor α, ECM: Extracellular matrix)
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Figure 4. Targeting the fibroblast for cardiac regeneration
Fibroblasts can be reprogrammed into cardiomyocytes using cocktails of reprogramming
factors. (A) In one approach, fibroblasts isolated from skin or other tissues of a ptient can be
transduced with cocktails of transcription factors to yield induced pluripotent stem cells (iPS
cells). Subsequently iPS cells generated from these fibroblasts can be differentiated in-vitro
into cardiomyocytes that could be subsequently transplanted into failing or injured hearts.
Alternatively combinations of factors can be used to directly reprogram the fibroblast to a
cardiomyocyte in-vitro bypassing the iPS step and then generated cardiomyocytes would be
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transplanted in a similar manner. (B) In an alternative approach, combinations of factors can
be directly delivered into the fibrotic region after cardiac injury. Cardiac fibroblasts in the
injury region can directly reprogram into cardiomyocytes that potentially can integrate with
existing cardiomyocytes to enhance cardiac function. By reprogramming fibroblasts in the
injury region to form cardiomyocytes, this strategy would also decrease fibrosis and
potentially ameliorate remodeling.
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Table 1
Changes in cardiac fibroblasts numbers from late development to adulthood in the murine heart. Adapted from
[3].
Developmental Stage Fraction of all heart cells
E18.5 14%
Post natal Day 1 10%
Post natal Day 5 14%
Post natal Day 15 18%
Adult 27%
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Table 2
Contribution of fibroblasts to the cellular composition of the adult murine and rat heart. (Numbers expressed
as a fraction of all heart cells). Adapted from [3].
Cell type Mouse Rat
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